Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
0(0%)
Results Posted
56%(5 trials)
Terminated
3(20%)

Phase Distribution

Ph phase_1
1
7%
Ph phase_4
3
20%
Ph not_applicable
1
7%
Ph phase_3
7
47%
Ph phase_2
2
13%

Phase Distribution

1

Early Stage

2

Mid Stage

10

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
2(14.3%)
Phase 3Large-scale testing
7(50.0%)
Phase 4Post-market surveillance
3(21.4%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.2%

9 of 13 finished

Non-Completion Rate

30.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(9)
Terminated(4)
Other(2)

Detailed Status

Completed9
Terminated3
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 22 (14.3%)
Phase 37 (50.0%)
Phase 43 (21.4%)
N/A1 (7.1%)

Trials by Status

terminated320%
withdrawn17%
unknown213%
completed960%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT03196466

Population Pharmacokinetics of Antiepileptic in Pediatrics

Completed
NCT03678129Not Applicable

GABA Pathways in Autism Spectrum Disorder (ASD)

Completed
NCT05697614Phase 4

The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children

Unknown
NCT02564952Phase 2

An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Completed
NCT02565108Phase 2

A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Completed
NCT03371836Phase 4

Use of Clobazam for Epilepsy and Anxiety

Completed
NCT02134366Phase 3

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

Terminated
NCT01160770Phase 3

Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT02187809Phase 3

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Terminated
NCT02726919Phase 4

Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy

Unknown
NCT01179828Phase 3

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

Completed
NCT02174094Phase 3

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Withdrawn
NCT01291316Phase 1

GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation

Completed
NCT01011036Phase 3

Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15